Skip to main content

Advertisement

SpringerLink
Log in

Patient Experience After Receiving a Diagnosis of Gastric Cancer in the USA

  • Original Research
  • Published:
Journal of Gastrointestinal Cancer Aims and scope Submit manuscript

Abstract

Purpose

This study investigated the patient perspective during cancer treatment and throughout the survivorship period and to understand how the patient experience may be related to choices for the treatment of gastric cancer.

Methods

Eligible patients in the Vector Oncology electronic medical records database were ≥18 years of age, diagnosed with gastric cancer, and received active treatment. Quality of life (QOL) was collected using the Patient Care Monitor (PCM). Time to deterioration in QOL and overall survival were measured, adjusting for demographic and baseline clinical characteristics. Logistic regression model and classification and regression trees (CART) were used to identify factors associated with treatment choice.

Results

There were 776 patients in this study, of whom 301 (38.8%) reported QOL data. Most patients reported problems on all PCM subscales; problems were more common during the treatment period. Median time to deterioration of PCM subscales ranged from 42 days for treatment side effects to 331 days for impaired performance. Median survival was low: 6.9 and 5.5 months from the start of first- and second-line therapy, respectively. The choices made between therapeutic options were primarily associated with the site at which the oncologist practiced.

Conclusions

Patients with gastric cancer report a considerable number of concerns on all subscales of the PCM, particularly during active treatment periods. The treatment heterogeneity and relative lack of clinical and symptom- or QOL-related factors associated with treatment choice suggest a gap in evidence that must be filled.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30.

    Article  PubMed  Google Scholar 

  2. Karve S et al. Treatment patterns, costs, and survival among Medicare-enrolled elderly patients diagnosed with advanced stage gastric cancer: analysis of a linked population-based cancer registry and administrative claims database. J Gastric Cancer. 2015;15(2):87–104.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Hess, L.M., et al., Chemotherapy treatment patterns, costs, and outcomes of patients with gastric cancer in the United States: a retrospective analysis of electronic medical record (EMR) and administrative claims data. Gastric Cancer, 2015.

  4. Fuchs CS et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014;383(9911):31–9.

    Article  CAS  PubMed  Google Scholar 

  5. Wilke H et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014;15(11):1224–35.

    Article  CAS  PubMed  Google Scholar 

  6. Al-Batran, S.E., et al., Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma. Ann Oncol, 2016.

  7. Chau I, Passalacqua R, Zalcberg JR, Fuchs CS, Liepa AM, Hsu Y, Schwartz JD, Koshiji M, Tabernero J. Tolerability and quality-of-life (QoL) results from the phase 3 REGARD study: Ramucirumab versus placebo in patients with previously treated gastric or gastroesophageal junction (GEJ) adenocarcinoma. EJC. 2013;4(Suppl 2):S615.

    Google Scholar 

  8. Fortner B et al. Validation of the Cancer Care Monitor items for physical symptoms and treatment side effects using expert oncology nurse evaluation. J Pain Symptom Manag. 2006;31(3):207–14.

    Article  Google Scholar 

  9. Fortner B et al. The Cancer Care Monitor: psychometric content evaluation and pilot testing of a computer administered system for symptom screening and quality of life in adult cancer patients. J Pain Symptom Manag. 2003;26(6):1077–92.

    Article  Google Scholar 

  10. Walker MS et al. Retrospective study of the effect of disease progression on patient reported outcomes in HER-2 negative metastatic breast cancer patients. Health Qual Life Outcomes. 2011;9:46.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Walker MS et al. Symptom burden and quality of life in patients with follicular lymphoma undergoing maintenance treatment with rituximab compared with observation. Ther Adv Hematol. 2011;2(3):129–39.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care. 2003;41(5):582–92.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Eli Lilly and Company, Indianapolis, IN, 46285, USA

    Lisa M Hess, Zhanglin Lin Cui, Xiaohong Li, Astra M Liepa, Sarah M Abraham & William Schelman

  2. inVentiv Health Clinical, Indianapolis, IN, 46202, USA

    Yixun Wu

Authors
  1. Lisa M Hess
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Zhanglin Lin Cui
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yixun Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Xiaohong Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Astra M Liepa
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Sarah M Abraham
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. William Schelman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lisa M Hess.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hess, L.M., Cui, Z.L., Wu, Y. et al. Patient Experience After Receiving a Diagnosis of Gastric Cancer in the USA. J Gastrointest Canc 49, 25–34 (2018). https://doi.org/10.1007/s12029-016-9904-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12029-016-9904-7

Keywords

Search

Navigation